*201 patients were randomised, 199 received ≥1 dose of the study treatment.2
†Cohort 2 rationale: Since major responses have not previously been observed in ibrutinib-treated patients with MYD88WT, patients found to have MYD88WT by gene sequencing (n=26) or those with unknown/inconclusive MYD88WT mutational status (n=2) were assigned to receive BRUKINSA in this separate single-arm exploratory analysis.5
‡Overall safety data are from the larger study population: BRUKINSA n=101, ibrutinib n=98. At >36 months: BRUKINSA n=72, ibrutinib n=64.3
¶BGGB-3111-LTE1 is a long-term extension study enrolling patients treated with BRUKINSA from parent trials treating B-cell malignancies.4
AE, adverse event; BID, twice daily; BTK, Bruton’s tyrosine kinase; CI, confidence interval; CNS, central nervous system; CR, complete response; CV, cardiovascular; DOR, duration of response; IRC, independent review committee; IWWM, International Workshop on Waldenström’s Macroglobulinaemia; MRR, major response rate; MUT, mutation; NE, non-evaluable; ORR, overall response rate; PD, progressive disease; PFS, progression-free survival; QD, once daily; R, randomisation; R/R, relapsed/refractory; TN, treatment naïve; VGPR(+), very good partial response (or better); WHIM, warts, hypogammaglobulinaemia infections, and myelokathexis; WM, Waldenström’s macroglobulinaemia; WT, wildtype.
References:
- BRUKINSA. United Kingdom Summary of Product Characteristics. BeiGene, Ltd;
- Tam CS, et al. Blood. 2020;136(18):2038–2050;
- Dimopoulos MA, et al. J Clin Oncol. 2023;41(33):5099–5106;
- D’Sa S, et al. ASH Annual Meeting, December 7–10, 2024. Poster 3031;
- Dimopoulos M, et al. Blood Adv. 2020;4(23):6009–6018;
- Tam CS, et al. Expert Rev Clin Pharmacol. 2021;14(11):1329–1344;
- Brullo C, et al. Int J Mol Sci. 2021;22(14):7641;
- Shadman M, et al. Lancet Haematol. 2023;10(1):e35–e45;
- Guo Y, et al. J Med Chem. 2019;62(17):7923–7940.
The study is registered with ClinicalTrials.gov: NCT03053440
▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
Adverse events should be reported. United Kingdom: Healthcare professionals are asked to report any suspected adverse reactions via Yellow Card Scheme found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to BeiGene at adverse_events@beigene.com
BRUKINSA and BeiGene are registered trademarks owned by BeiGene, Ltd. Copyright © 2025, BeiGene. All rights reserved.